Skip to Content
Merck
  • Plasma and erythrocyte uptake of omega-3 fatty acids from an intravenous fish oil based lipid emulsion in patients with advanced oesophagogastric cancer.

Plasma and erythrocyte uptake of omega-3 fatty acids from an intravenous fish oil based lipid emulsion in patients with advanced oesophagogastric cancer.

Clinical nutrition (Edinburgh, Scotland) (2016-06-28)
A M Eltweri, A L Thomas, H L Fisk, A Arshad, P C Calder, A R Dennison, D J Bowrey
ABSTRACT

It has been demonstrated that short term intravenous (IV) administration of omega-3 polyunsaturated fatty acids (PUFAs) is more effective than oral supplementation at promoting incorporation of the bioactive omega-3 PUFAs eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) into plasma, blood cells and tissues. The effect of repeated short term IV infusion of omega-3 PUFAs was investigated in patients with advanced oesophagogastric cancer during palliative chemotherapy. Patients with advanced oesophagogastric cancer (n = 21) were recruited into a phase II pilot clinical trial. All patients were scheduled for an intravenous infusion of Omegaven Twenty patients received at least one Omegaven Repeated weekly omega-3 PUFA infusion is effective in enriching plasma PC and RBC membranes in EPA in patients with advanced oesophagogastric cancer receiving palliative chemotherapy. Clinical Trials.Gov NCT01870791.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
all-cis-7,10,13,16,19-Docosapentaenoic acid, synthetic, ≥97%
SKU
Pack Size
Availability
Price
Quantity